Type 5 cyclic nucleotide phosphodiesterase inhibitor - Takeda

Drug Profile

Type 5 cyclic nucleotide phosphodiesterase inhibitor - Takeda

Alternative Names: PDE5 inhibitor - Nycomed; PDE5 inhibitor - Takeda

Latest Information Update: 11 Apr 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory tract disorders

Most Recent Events

  • 01 Apr 2012 Discontinued - Phase-I for Respiratory tract disorders in Europe (unspecified route)
  • 30 Sep 2011 Nycomed has been acquired by Takeda
  • 14 Oct 2009 Phase-I clinical trials in Respiratory tract disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top